Relmada Therapeutics, Inc. (RLMD) 10-Year Financial Performance & Capital Metrics

RLMD • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.Show more

Revenue $0
EBITDA -$84M
Net Income -$80M +19.0%
EPS (Diluted) -2.65 +19.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -132.33% -51.2%
ROIC -111.43% -54.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM37.28%

ROCE

10Y Avg-154.19%

5Y Avg-91.65%

3Y Avg-107.71%

Latest-138.8%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	54.82K	85.27K	2.63K	4.87K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-54.82K	-85.27K	-2.63K	-4.87K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-4.92%	-0.56%	0.97%	-0.85%	1%	-	-	-	-	-
Operating Expenses+	16.22M	7.22M	6.92M	12.73M	15.11M	60.84M	125.7M	161.25M	103.7M	83.89M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	9.88M	5.71M	3.98M	5.7M	7.25M	24.87M	35.08M	47.93M	48.9M	37.72M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	6.21M	1.29M	2.94M	7.03M	7.86M	35.97M	90.62M	113.32M	54.81M	46.18M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	130.27K	0	2.35K	0	0	0	0	923	0	0
Operating Income+	-16.22M	-7.22M	-6.92M	-12.73M	-15.11M	-60.84M	-125.7M	-161.25M	-103.7M	-83.89M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.05%	0.55%	0.04%	-0.84%	-0.19%	-3.03%	-1.07%	-0.28%	0.36%	0.19%
EBITDA+	-16.16M	-7.13M	-6.91M	-12.72M	-15.1M	-60.83M	-125.7M	-161.25M	0	-83.89M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.05%	0.56%	0.03%	-0.84%	-0.19%	-3.03%	-1.07%	-0.28%	1%	-
D&A (Non-Cash Add-back)	54.82K	85.27K	2.63K	4.87K	4.36K	3.75K	1.26K	2K	103.7M	0
EBIT	-16.09M	-7.01M	-6.92M	-16.56M	-15.11M	-59.34M	-125.7M	-161.25M	-98.79M	-83.89M
Net Interest Income+	0	-550	-1.34M	0	104	1.4M	1.2M	2.66M	5.15M	3.53M
Interest Income	1.75K	0	0	-761K	104	1.4M	1.2M	2.66M	5.15M	3.53M
Interest Expense	0	550	1.34M	0	0	0	0	0	0	0
Other Income/Expense	13.24M	932.31K	-2.04M	-5.7M	104.11K	1.38M	-48.32K	4.21M	4.91M	3.91M
Pretax Income+	-2.98M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	4.59M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.98M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.86%	-1.11%	-0.43%	-0.93%	0.13%	-2.96%	-1.12%	-0.25%	0.37%	0.19%
Net Income (Continuing)	-2.98M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.03	-2.08	-2.86	-2.74	-1.63	-3.81	-7.16	-5.30	-3.28	-2.65
EPS Growth %	0.88%	-1.02%	-0.38%	0.04%	0.41%	-1.34%	-0.88%	0.26%	0.38%	0.19%
EPS (Basic)	-1.03	-2.08	-2.86	-2.74	-1.63	-3.81	-7.16	-5.30	-3.28	-2.65
Diluted Shares Outstanding	2.9M	3.02M	3.14M	6.31M	9.23M	15.59M	17.55M	29.63M	30.1M	30.16M
Basic Shares Outstanding	2.9M	3.02M	3.14M	6.31M	9.23M	15.59M	17.55M	29.63M	30.1M	30.16M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.3M	2.47M	2.74M	9.98M	116.94M	118.07M	223.3M	152.87M	97.51M	45.8M
Cash & Short-Term Investments	8.5M	1.71M	2.24M	9.22M	116.44M	117.09M	211.91M	148.32M	96.32M	44.91M
Cash Only	8.5M	1.71M	2.24M	9.22M	36.28M	2.5M	44.44M	5.4M	4.09M	3.86M
Short-Term Investments	0	0	0	0	80.16M	114.6M	167.47M	142.93M	92.23M	41.05M
Accounts Receivable	0	291.92K	72.1K	247.08K	73.09K	79.46K	86.38K	512.43K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	534.8K	472.5K	426.9K	459K	0	0	0	0	0	0
Days Inventory Outstanding	3.56K	2.02K	59.31K	34.4K	-	-	-	-	-	-
Other Current Assets	231.94K	125.19K	0	0	46	-10	35	0	0	0
Total Non-Current Assets+	945.7K	362.01K	310.11K	235.35K	196K	112.64K	28.29K	34.88K	43.13K	21.98K
Property, Plant & Equipment	531.35K	2.31K	12.08K	7.21K	5.01K	1.26K	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	390.8K	337.73K	273.24K	203.14K	0	0	0	0	0	0
Other Non-Current Assets	23.55K	21.96K	24.79K	25K	190.99K	111.38K	28.29K	34.88K	43.13K	21.98K
Total Assets+	10.24M	2.84M	3.05M	10.22M	117.14M	118.19M	223.33M	152.91M	97.55M	45.82M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.58%	-0.72%	0.07%	2.35%	10.46%	0.01%	0.89%	-0.32%	-0.36%	-0.53%
Total Current Liabilities+	3.06M	1.38M	5.9M	2.61M	1.46M	12.6M	15.06M	12.47M	12.19M	10.29M
Accounts Payable	1.26M	529.56K	765.44K	924.36K	522.66K	8.35M	11.19M	5.26M	3.51M	4.13M
Days Payables Outstanding	8.39K	2.27K	106.35K	69.28K	-	-	-	-	-	-
Short-Term Debt	273.67K	276.67K	285.17K	364.2K	110.25K	0	0	0	0	0
Deferred Revenue (Current)	634.9K	394.6K	659.5K	1000K	0	0	0	0	0	0
Other Current Liabilities	892.5K	513.55K	4.81M	-45	250K	1.8M	1.64M	1.02M	5.68M	1.15M
Current Ratio	3.04x	1.80x	0.46x	3.83x	80.21x	9.37x	14.83x	12.26x	8.00x	4.45x
Quick Ratio	2.86x	1.45x	0.39x	3.65x	80.21x	9.37x	14.83x	12.26x	8.00x	4.45x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	140.91K	0	2.66M	0	0	0	0	0	0	4.47K
Long-Term Debt	0	0	2.66M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	140.91K	0	0	0	0	0	0	0	0	4.47K
Total Liabilities	3.2M	1.38M	8.56M	2.61M	1.46M	12.6M	15.06M	12.47M	12.19M	10.3M
Total Debt+	273.67K	276.67K	2.94M	364.2K	110.25K	0	0	0	0	0
Net Debt	-8.23M	-1.43M	702.68K	-8.85M	-36.17M	-2.5M	-44.44M	-5.4M	-4.09M	-3.86M
Debt / Equity	0.04x	0.19x	-	0.05x	0.00x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-13125.45x	-5.17x	-	-	-	-	-	-	-
Total Equity+	7.04M	1.46M	-5.51M	7.61M	115.68M	105.58M	208.26M	140.44M	85.36M	35.52M
Equity Growth %	-0.2%	-0.79%	-4.78%	2.38%	14.19%	-0.09%	0.97%	-0.33%	-0.39%	-0.58%
Book Value per Share	2.43	0.48	-1.76	1.21	12.53	6.77	11.87	4.74	2.84	1.18
Total Shareholders' Equity	7.04M	1.46M	-5.51M	7.61M	115.68M	105.58M	208.26M	140.44M	85.36M	35.52M
Common Stock	12.04K	12.53K	3.14K	9.74K	14.46K	16.33K	27.74K	30.1K	30.1K	30.17K
Retained Earnings	-79.1M	-85.38M	-94.34M	-111.66M	-119.86M	-179.32M	-305.07M	-462.11M	-560.9M	-640.88M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.14M	-6.47M	-6M	-10.5M	-12.09K	-27.81M	-91.87M	-103.8M	-51.66M	-51.76M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.19%	0.51%	0.07%	-0.75%	1%	-2298.77%	-2.3%	-0.13%	0.5%	-0%
Net Income	-2.97M	-6.29M	-8.96M	-17.32M	-15.01K	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Depreciation & Amortization	54.82K	85.27K	2.63K	4.87K	4	3.75K	1.26K	0	0	0
Stock-Based Compensation	1.21M	704.45K	518K	1.21M	2.76K	20.78M	40.49M	44.19M	0	30.19M
Deferred Taxes	-13.31M	-620.25K	708.9K	3.83M	0	0	0	0	0	0
Other Non-Cash Items	-13.11M	-721.84K	1.03M	266.76K	173	16.95K	1.25M	-1.55M	44.05M	-381.66K
Working Capital Changes	1.68M	-247.69K	700.06K	1.51M	-26	10.85M	-7.86M	10.59M	3.08M	-1.58M
Change in Receivables	-232	-655	224.98K	-169.36K	0	73.09K	79.46K	-426.06K	512.43K	0
Change in Inventory	0	0	0	169.36K	0	0	0	0	0	0
Change in Payables	424.43K	-730.15K	157.39K	158.92K	0	7.82M	2.85M	421.04K	-1.76M	624.55K
Cash from Investing+	-562.26K	-49.69K	-12.39K	0	-80.16K	-34.45M	-54.12M	19.73M	50.45M	51.56M
Capital Expenditures	-562.26K	-49.69K	-12.39K	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-80.16K	0	0	0	0	0
Cash from Financing+	-263.75K	-273.67K	6.54M	17.48M	126.11K	28.47M	187.94M	45.02M	-98.46K	-40.34K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	126.11K	8.06M	2.63M	2.29M	-98.46K	-287.09K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.71M	-6.52M	-6.01M	-10.5M	-12.09K	-27.81M	-91.87M	-103.8M	-51.66M	-51.76M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.16%	0.52%	0.08%	-0.75%	1%	-2298.77%	-2.3%	-0.13%	0.5%	-0%
FCF per Share	-4.73	-2.16	-1.92	-1.66	-0.00	-1.78	-5.23	-3.50	-1.72	-1.72
FCF Conversion (FCF/Net Income)	4.42x	1.03x	0.67x	0.61x	0.00x	0.47x	0.73x	0.66x	0.52x	0.65x
Interest Paid	0	0	0	0	0	2.42K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-37.53%	-147.88%	-	-1649.15%	-24.34%	-53.74%	-80.14%	-90.07%	-87.51%	-132.33%
Return on Invested Capital (ROIC)	-	-	-	-	-28.96%	-49.98%	-70.64%	-80.93%	-71.91%	-111.43%
Debt / Equity	0.04x	0.19x	-	0.05x	0.00x	-	-	-	-	-
Interest Coverage	-	-13125.45x	-5.17x	-	-	-	-	-	-	-
FCF Conversion	4.42x	1.03x	0.67x	0.61x	0.00x	0.47x	0.73x	0.66x	0.52x	0.65x

Frequently Asked Questions

Growth & Financials

Relmada Therapeutics, Inc. (RLMD) grew revenue by 0.0% over the past year. Growth has been modest.

Relmada Therapeutics, Inc. (RLMD) reported a net loss of $56.2M for fiscal year 2024.

Dividend & Returns

Relmada Therapeutics, Inc. (RLMD) has a return on equity (ROE) of -132.3%. Negative ROE indicates the company is unprofitable.

Relmada Therapeutics, Inc. (RLMD) had negative free cash flow of $40.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Relmada Therapeutics, Inc. (RLMD) 10-Year Financial Performance & Capital Metrics

RLMD • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$84M
Net Income -$80M +19.0%
EPS (Diluted) -2.65 +19.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -132.33% -51.2%
ROIC -111.43% -54.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM35.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM37.28%

ROCE

10Y Avg-154.19%

5Y Avg-91.65%

3Y Avg-107.71%

Latest-138.8%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	54.82K	85.27K	2.63K	4.87K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-54.82K	-85.27K	-2.63K	-4.87K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-4.92%	-0.56%	0.97%	-0.85%	1%	-	-	-	-	-
Operating Expenses+	16.22M	7.22M	6.92M	12.73M	15.11M	60.84M	125.7M	161.25M	103.7M	83.89M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	9.88M	5.71M	3.98M	5.7M	7.25M	24.87M	35.08M	47.93M	48.9M	37.72M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	6.21M	1.29M	2.94M	7.03M	7.86M	35.97M	90.62M	113.32M	54.81M	46.18M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	130.27K	0	2.35K	0	0	0	0	923	0	0
Operating Income+	-16.22M	-7.22M	-6.92M	-12.73M	-15.11M	-60.84M	-125.7M	-161.25M	-103.7M	-83.89M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.05%	0.55%	0.04%	-0.84%	-0.19%	-3.03%	-1.07%	-0.28%	0.36%	0.19%
EBITDA+	-16.16M	-7.13M	-6.91M	-12.72M	-15.1M	-60.83M	-125.7M	-161.25M	0	-83.89M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.05%	0.56%	0.03%	-0.84%	-0.19%	-3.03%	-1.07%	-0.28%	1%	-
D&A (Non-Cash Add-back)	54.82K	85.27K	2.63K	4.87K	4.36K	3.75K	1.26K	2K	103.7M	0
EBIT	-16.09M	-7.01M	-6.92M	-16.56M	-15.11M	-59.34M	-125.7M	-161.25M	-98.79M	-83.89M
Net Interest Income+	0	-550	-1.34M	0	104	1.4M	1.2M	2.66M	5.15M	3.53M
Interest Income	1.75K	0	0	-761K	104	1.4M	1.2M	2.66M	5.15M	3.53M
Interest Expense	0	550	1.34M	0	0	0	0	0	0	0
Other Income/Expense	13.24M	932.31K	-2.04M	-5.7M	104.11K	1.38M	-48.32K	4.21M	4.91M	3.91M
Pretax Income+	-2.98M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	4.59M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.98M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.86%	-1.11%	-0.43%	-0.93%	0.13%	-2.96%	-1.12%	-0.25%	0.37%	0.19%
Net Income (Continuing)	-2.98M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.03	-2.08	-2.86	-2.74	-1.63	-3.81	-7.16	-5.30	-3.28	-2.65
EPS Growth %	0.88%	-1.02%	-0.38%	0.04%	0.41%	-1.34%	-0.88%	0.26%	0.38%	0.19%
EPS (Basic)	-1.03	-2.08	-2.86	-2.74	-1.63	-3.81	-7.16	-5.30	-3.28	-2.65
Diluted Shares Outstanding	2.9M	3.02M	3.14M	6.31M	9.23M	15.59M	17.55M	29.63M	30.1M	30.16M
Basic Shares Outstanding	2.9M	3.02M	3.14M	6.31M	9.23M	15.59M	17.55M	29.63M	30.1M	30.16M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.3M	2.47M	2.74M	9.98M	116.94M	118.07M	223.3M	152.87M	97.51M	45.8M
Cash & Short-Term Investments	8.5M	1.71M	2.24M	9.22M	116.44M	117.09M	211.91M	148.32M	96.32M	44.91M
Cash Only	8.5M	1.71M	2.24M	9.22M	36.28M	2.5M	44.44M	5.4M	4.09M	3.86M
Short-Term Investments	0	0	0	0	80.16M	114.6M	167.47M	142.93M	92.23M	41.05M
Accounts Receivable	0	291.92K	72.1K	247.08K	73.09K	79.46K	86.38K	512.43K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	534.8K	472.5K	426.9K	459K	0	0	0	0	0	0
Days Inventory Outstanding	3.56K	2.02K	59.31K	34.4K	-	-	-	-	-	-
Other Current Assets	231.94K	125.19K	0	0	46	-10	35	0	0	0
Total Non-Current Assets+	945.7K	362.01K	310.11K	235.35K	196K	112.64K	28.29K	34.88K	43.13K	21.98K
Property, Plant & Equipment	531.35K	2.31K	12.08K	7.21K	5.01K	1.26K	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	390.8K	337.73K	273.24K	203.14K	0	0	0	0	0	0
Other Non-Current Assets	23.55K	21.96K	24.79K	25K	190.99K	111.38K	28.29K	34.88K	43.13K	21.98K
Total Assets+	10.24M	2.84M	3.05M	10.22M	117.14M	118.19M	223.33M	152.91M	97.55M	45.82M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.58%	-0.72%	0.07%	2.35%	10.46%	0.01%	0.89%	-0.32%	-0.36%	-0.53%
Total Current Liabilities+	3.06M	1.38M	5.9M	2.61M	1.46M	12.6M	15.06M	12.47M	12.19M	10.29M
Accounts Payable	1.26M	529.56K	765.44K	924.36K	522.66K	8.35M	11.19M	5.26M	3.51M	4.13M
Days Payables Outstanding	8.39K	2.27K	106.35K	69.28K	-	-	-	-	-	-
Short-Term Debt	273.67K	276.67K	285.17K	364.2K	110.25K	0	0	0	0	0
Deferred Revenue (Current)	634.9K	394.6K	659.5K	1000K	0	0	0	0	0	0
Other Current Liabilities	892.5K	513.55K	4.81M	-45	250K	1.8M	1.64M	1.02M	5.68M	1.15M
Current Ratio	3.04x	1.80x	0.46x	3.83x	80.21x	9.37x	14.83x	12.26x	8.00x	4.45x
Quick Ratio	2.86x	1.45x	0.39x	3.65x	80.21x	9.37x	14.83x	12.26x	8.00x	4.45x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	140.91K	0	2.66M	0	0	0	0	0	0	4.47K
Long-Term Debt	0	0	2.66M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	140.91K	0	0	0	0	0	0	0	0	4.47K
Total Liabilities	3.2M	1.38M	8.56M	2.61M	1.46M	12.6M	15.06M	12.47M	12.19M	10.3M
Total Debt+	273.67K	276.67K	2.94M	364.2K	110.25K	0	0	0	0	0
Net Debt	-8.23M	-1.43M	702.68K	-8.85M	-36.17M	-2.5M	-44.44M	-5.4M	-4.09M	-3.86M
Debt / Equity	0.04x	0.19x	-	0.05x	0.00x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-13125.45x	-5.17x	-	-	-	-	-	-	-
Total Equity+	7.04M	1.46M	-5.51M	7.61M	115.68M	105.58M	208.26M	140.44M	85.36M	35.52M
Equity Growth %	-0.2%	-0.79%	-4.78%	2.38%	14.19%	-0.09%	0.97%	-0.33%	-0.39%	-0.58%
Book Value per Share	2.43	0.48	-1.76	1.21	12.53	6.77	11.87	4.74	2.84	1.18
Total Shareholders' Equity	7.04M	1.46M	-5.51M	7.61M	115.68M	105.58M	208.26M	140.44M	85.36M	35.52M
Common Stock	12.04K	12.53K	3.14K	9.74K	14.46K	16.33K	27.74K	30.1K	30.1K	30.17K
Retained Earnings	-79.1M	-85.38M	-94.34M	-111.66M	-119.86M	-179.32M	-305.07M	-462.11M	-560.9M	-640.88M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.14M	-6.47M	-6M	-10.5M	-12.09K	-27.81M	-91.87M	-103.8M	-51.66M	-51.76M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.19%	0.51%	0.07%	-0.75%	1%	-2298.77%	-2.3%	-0.13%	0.5%	-0%
Net Income	-2.97M	-6.29M	-8.96M	-17.32M	-15.01K	-59.46M	-125.75M	-157.04M	-98.79M	-79.98M
Depreciation & Amortization	54.82K	85.27K	2.63K	4.87K	4	3.75K	1.26K	0	0	0
Stock-Based Compensation	1.21M	704.45K	518K	1.21M	2.76K	20.78M	40.49M	44.19M	0	30.19M
Deferred Taxes	-13.31M	-620.25K	708.9K	3.83M	0	0	0	0	0	0
Other Non-Cash Items	-13.11M	-721.84K	1.03M	266.76K	173	16.95K	1.25M	-1.55M	44.05M	-381.66K
Working Capital Changes	1.68M	-247.69K	700.06K	1.51M	-26	10.85M	-7.86M	10.59M	3.08M	-1.58M
Change in Receivables	-232	-655	224.98K	-169.36K	0	73.09K	79.46K	-426.06K	512.43K	0
Change in Inventory	0	0	0	169.36K	0	0	0	0	0	0
Change in Payables	424.43K	-730.15K	157.39K	158.92K	0	7.82M	2.85M	421.04K	-1.76M	624.55K
Cash from Investing+	-562.26K	-49.69K	-12.39K	0	-80.16K	-34.45M	-54.12M	19.73M	50.45M	51.56M
Capital Expenditures	-562.26K	-49.69K	-12.39K	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-80.16K	0	0	0	0	0
Cash from Financing+	-263.75K	-273.67K	6.54M	17.48M	126.11K	28.47M	187.94M	45.02M	-98.46K	-40.34K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	126.11K	8.06M	2.63M	2.29M	-98.46K	-287.09K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.71M	-6.52M	-6.01M	-10.5M	-12.09K	-27.81M	-91.87M	-103.8M	-51.66M	-51.76M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.16%	0.52%	0.08%	-0.75%	1%	-2298.77%	-2.3%	-0.13%	0.5%	-0%
FCF per Share	-4.73	-2.16	-1.92	-1.66	-0.00	-1.78	-5.23	-3.50	-1.72	-1.72
FCF Conversion (FCF/Net Income)	4.42x	1.03x	0.67x	0.61x	0.00x	0.47x	0.73x	0.66x	0.52x	0.65x
Interest Paid	0	0	0	0	0	2.42K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-37.53%	-147.88%	-	-1649.15%	-24.34%	-53.74%	-80.14%	-90.07%	-87.51%	-132.33%
Return on Invested Capital (ROIC)	-	-	-	-	-28.96%	-49.98%	-70.64%	-80.93%	-71.91%	-111.43%
Debt / Equity	0.04x	0.19x	-	0.05x	0.00x	-	-	-	-	-
Interest Coverage	-	-13125.45x	-5.17x	-	-	-	-	-	-	-
FCF Conversion	4.42x	1.03x	0.67x	0.61x	0.00x	0.47x	0.73x	0.66x	0.52x	0.65x

Frequently Asked Questions

Growth & Financials

Relmada Therapeutics, Inc. (RLMD) grew revenue by 0.0% over the past year. Growth has been modest.

Relmada Therapeutics, Inc. (RLMD) reported a net loss of $56.2M for fiscal year 2024.

Dividend & Returns

Relmada Therapeutics, Inc. (RLMD) has a return on equity (ROE) of -132.3%. Negative ROE indicates the company is unprofitable.

Relmada Therapeutics, Inc. (RLMD) had negative free cash flow of $40.0M in fiscal year 2024, likely due to heavy capital investments.